| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0091-6749(00)90092-7 |
| P698 | PubMed publication ID | 10669863 |
| P50 | author | Lawrence M. Lichtenstein | Q112477025 |
| Anne Kagey-Sobotka | Q123536695 | ||
| P2093 | author name string | Golden DB | |
| P2860 | cites work | Treatment Failures With Whole-Body Extract Therapy of Insect Sting Allergy | Q34284086 |
| Natural history of Hymenoptera venom sensitivity in adults | Q41686860 | ||
| Discontinuing venom immunotherapy: extended observations | Q41731183 | ||
| Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. | Q50912595 | ||
| Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety | Q52445480 | ||
| Clinical and immunologic follow-up of patients who stop venom immunotherapy. | Q52446972 | ||
| Venom immunotherapy: when is it reasonable to stop. | Q52448110 | ||
| Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. | Q52448117 | ||
| Prospective observations on stopping prolonged venom immunotherapy. | Q52455145 | ||
| Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. | Q52543080 | ||
| Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. | Q52544334 | ||
| Discontinuing venom immunotherapy: outcome after five years. | Q52547608 | ||
| Epidemiology of Insect Venom Sensitivity | Q59346023 | ||
| Guidelines for venom immunotherapy | Q69492758 | ||
| Clinical and immunologic observations in patients who stop venom immunotherapy | Q70018359 | ||
| Releasability of human basophils: Cellular sensitivity and maximal histamine release are independent variables | Q72070626 | ||
| Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients | Q74587038 | ||
| P433 | issue | 2 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 385-390 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | Survey of patients after discontinuing venom immunotherapy. | |
| P478 | volume | 105 |
| Q51732967 | A 5-year venom immunotherapy protocol with 50 μg maintenance dose: safety and efficacy in school children. |
| Q50788965 | Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom. |
| Q36834569 | Allergen immunotherapy: a centenary celebration |
| Q35210357 | Allergic reactions to Triatoma bites |
| Q30047515 | Allergy Diagnostic Testing: An Updated Practice Parameter |
| Q37253374 | Can we produce true tolerance in patients with food allergy? |
| Q37822834 | Clinical immunology review series: an approach to desensitization |
| Q52657189 | Comparison of 2 maintenance doses (100 microg vs 200 microg) in Hymenoptera venom immunotherapy: influence of the maintenance dose on the immunologic response. |
| Q40744033 | Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI). |
| Q39716681 | Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines |
| Q36829985 | Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? |
| Q38658310 | EAACI Guidelines on Allergen Immunotherapy: Hymenoptera venom allergy. |
| Q58617547 | Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy |
| Q37842330 | Hymenoptera venom immunotherapy |
| Q48243376 | Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects. |
| Q36273406 | Immunotherapy of hypersensitivity to hymenoptera venom |
| Q52681291 | Influence of total IgE levels on the severity of sting reactions in Hymenoptera venom allergy. |
| Q37931150 | Insect allergy |
| Q36404340 | Insect sting allergy and venom immunotherapy |
| Q24672123 | Insect sting anaphylaxis |
| Q38542313 | Is clinical tolerance possible after allergen immunotherapy? |
| Q38852323 | Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines |
| Q52689135 | Long-term efficacy of venom immunotherapy. |
| Q24631273 | Management of insect sting hypersensitivity: an update |
| Q36180099 | Oral immunotherapy for treatment of egg allergy in children |
| Q52705797 | P38 mitogen-activated protein kinase signal transduction in the diagnosis and follow up of immunotherapy of wasp venom allergy. |
| Q91837709 | Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy |
| Q45215828 | Reactions to insect bites and stings: what about the orphan insects? |
| Q28547393 | Risk associated with bee venom therapy: a systematic review and meta-analysis |
| Q37924818 | Safety of hymenoptera venom immunotherapy: a systematic review |
| Q37355616 | Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom |
| Q44855659 | Specific ultrarush desensitization in Hymenoptera venom-allergic patients |
| Q26801123 | Stinging insect allergy: current perspectives on venom immunotherapy |
| Q38025664 | Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations |
| Q45050084 | The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study |
| Q45732412 | Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective |
| Q46248572 | Venom immunotherapy in patients with allergic reactions to insect stings |
Search more.